What is INCY stock price today?

INCY (Incyte Corp) stock is trading at $101.27 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is INCY stock going up or down today?

INCY stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy INCY stock now?

The decision to buy INCY depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is INCY a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for INCY based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is INCY stock overvalued or undervalued?

INCY currently trades at a P/E ratio of 15.61 relative to earnings. Our DCF calculator provides intrinsic value estimates to help determine if INCY is fairly priced.

What is INCY's P/E ratio?

INCY has a price-to-earnings (P/E) ratio of 15.61, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is INCY's market cap?

INCY (Incyte Corp) has a market capitalization of $19.92 billion, making it a mid-cap stock.

What is INCY's price to book ratio?

INCY trades at a price-to-book (P/B) ratio of 4.04, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does INCY pay dividends?

INCY does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is INCY's dividend yield?

INCY does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is INCY stock a good long-term investment?

INCY's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is INCY's revenue growth rate?

INCY has shown revenue growth of 0.3% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, INCY is profitable with a profit margin of 0.3%. This indicates the company generates 0.3 cents of profit for every dollar of revenue.

What are the risks of investing in INCY?

Key risks for INCY include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does INCY compare to its competitors?

Compare INCY to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize INCY's performance and positioning.

What is INCY's stock price target for 2026?

Our AI model provides price targets for INCY based on fundamental analysis: Bull case $131.65 (+30%), Base case $116.46 (+15%), Bear case $91.14 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about INCY?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for INCY. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is INCY's next earnings report?

INCY reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

INCY - Incyte Corp

NYSE * Health Care * Biotechnology

$101.27

+$1.18 (+1.18%)

About Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

INCY Key Statistics

Market Cap

$19.92B

P/E Ratio

15.61

P/B Ratio

4.04

EPS

$6.41

Revenue Growth

+0.3%

Profit Margin

0.3%

Employees

2,844

How INCY Compares to Peers

INCY has the lowest P/E ratio in Biotechnology, suggesting it may be the most undervalued

INCY has the fastest revenue growth among competitors

INCY is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
INCY(This stock)	$19.92B	15.6	0%	0.3%	-
AMGNAmgen Inc	$204.48B	26.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$178.37B	21.2	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$121.95B	31.3	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$81.49B	18.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$28.15B	21.8	-0%	0.1%	vs BIIB

Incyte Corp Company Information

Headquarters: Delaware; U.S.A
Website: www.incyte.com
Sector: Health Care
Industry: Biotechnology

INCY - Incyte Corp

About Incyte Corp

INCY Key Statistics

How INCY Compares to Peers

Incyte Corp Company Information

INCY Lician Score

INCY Financial Snowflake

Upcoming Events for INCY